Balance Sheet
Cash Flow Statement
Amortizatization of IntangiblesAsset Writedowns and ImpairmentCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in Acquisitions & DivestmentsChange in CashChange in ReceivablesDepreciation & Amortization (CF)Depreciation and DepletionFree Cash FlowNet Cash FlowNet IncomeOther financing activitiesShare-based CompensationShares IssuedShares Repurchased
Daily Values
Growth Metrics
Income Statement
Others
Ratios

C4 Therapeutics (CCCC) Change in Acquisitions & Divestments (2019 - 2025)

Historic Change in Acquisitions & Divestments for C4 Therapeutics (CCCC) over the last 6 years, with Q3 2025 value amounting to $51.2 million.

  • C4 Therapeutics' Change in Acquisitions & Divestments fell 2551.74% to $51.2 million in Q3 2025 from the same period last year, while for Sep 2025 it was $221.5 million, marking a year-over-year decrease of 499.16%. This contributed to the annual value of $233.2 million for FY2024, which is 1956.3% down from last year.
  • C4 Therapeutics' Change in Acquisitions & Divestments amounted to $51.2 million in Q3 2025, which was down 2551.74% from $60.8 million recorded in Q2 2025.
  • C4 Therapeutics' 5-year Change in Acquisitions & Divestments high stood at $115.0 million for Q1 2021, and its period low was $51.2 million during Q3 2025.
  • Moreover, its 5-year median value for Change in Acquisitions & Divestments was $65.7 million (2022), whereas its average is $69.6 million.
  • The largest annual percentage gain for C4 Therapeutics' Change in Acquisitions & Divestments in the last 5 years was 4484.51% (2022), contrasted with its biggest fall of 3705.15% (2022).
  • C4 Therapeutics' Change in Acquisitions & Divestments (Quarter) stood at $86.1 million in 2021, then dropped by 22.12% to $67.1 million in 2022, then rose by 4.35% to $70.0 million in 2023, then fell by 22.19% to $54.4 million in 2024, then dropped by 6.01% to $51.2 million in 2025.
  • Its Change in Acquisitions & Divestments was $51.2 million in Q3 2025, compared to $60.8 million in Q2 2025 and $54.8 million in Q1 2025.